A senior federal health official says a key research agency has begun reversing years of mission drift and returning to its core responsibility of improving patient outcomes, safety, and efficiency in the U.S. healthcare system. In an interview with Dan Proft, Roger Klein, director of the Agency for Healthcare Research and Quality, described what he characterized as a significant reorientation following what he said was a period of politicization under the previous administration.
Klein said the agency, commonly known as AHRQ, was established to conduct evidence-based research aimed at reducing medical errors, improving clinical effectiveness, and ensuring patients receive appropriate care. He argued that in recent years the agency had shifted away from those objectives, devoting increasing attention to broader social and ideological goals that he said were not supported by rigorous scientific evidence. According to Klein, priorities such as systemic racism and equity became central organizing principles, displacing traditional measures of quality and safety that directly affect patient care.
The change, Klein said, reflected a broader trend across federal agencies during the administration of Joe Biden, in which political and ideological considerations increasingly shaped research agendas and performance evaluations. He noted that concepts unrelated to healthcare delivery, including climate change and social justice frameworks, were incorporated into internal reviews and expectations for agency staff. Klein argued that this approach mirrored problems seen during the pandemic, when public health guidance was widely criticized for being influenced by political considerations rather than strictly by data.
Since assuming leadership, Klein said the agency has begun an internal review of its programs, standards, and research priorities with the goal of restoring its statutory mission. He credited support from Donald Trump and Department of Health and Human Services leadership for enabling the changes, describing a concerted effort to remove ideological requirements from agency operations and refocus on measurable improvements in healthcare delivery.
Klein acknowledged that the process has been challenging, particularly because prior policies had been embedded in performance metrics and institutional practices. He said that recent workforce reductions, while controversial, created an opportunity to reset expectations and rebuild around core competencies. According to Klein, remaining staff have generally been cooperative, though he noted that long-established habits and assumptions take time to change.
He argued that AHRQ’s influence extends well beyond its own research portfolio, shaping standards and priorities across the broader healthcare research community. For that reason, Klein said, restoring a narrow focus on evidence, outcomes, and patient safety could have ripple effects throughout academic medicine and health policy. He described the effort as essential not only to the agency’s credibility, but to the integrity of federal healthcare research more broadly.
Klein concluded that a depoliticized bureaucracy is critical to effective governance, particularly in agencies charged with protecting public health. He said that returning AHRQ to its original mission is a necessary step toward ensuring that federal research serves patients rather than political causes.